SSKN · As filed with the SEC

STRATA Skin Sciences income statement, by quarter

The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Operations · USD thousands, except per-share amounts

USD thousands, except per-share amountsQ4 2025†
3 months ended Dec 31, 2025
Q3 2025
3 months ended Sep 30, 2025
Q2 2025
3 months ended Jun 30, 2025
Q1 2025
3 months ended Mar 31, 2025
Revenues, net9,292†6,9297,6636,812
Cost of revenues3,678†2,7453,3573,165
Gross profit5,614†4,1844,3063,647
Operating expenses:
Engineering and product development67†1728696
Selling and marketing3,254†3,2013,5332,993
General and administrative2,256†2,6682,9112,573
Settlement gains—(684)——
Total operating expenses5,126†5,3576,5305,662
Loss from operations488†(1,173)(2,224)(2,015)
Interest expense(484)†(498)(491)(486)
Interest income66†4922669
Other income0†00—
Other (expense), income net(418)†(449)(265)(417)
Net loss58†(1,622)(2,489)(2,432)
Net loss per share of common stock - basic (in Dollars per share)—(0.36)(0.60)(0.58)
Net loss per share of common stock - diluted (in Dollars per share)—(0.36)(0.60)(0.58)
Weighted average shares of common stock outstanding - basic (in Shares)—4,481,3374,171,1614,171,161
Weighted average shares of common stock outstanding - diluted (in Shares)—4,481,3374,171,1614,171,161

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.